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Introduction: Ex vivo experiments in extracorporeal membrane oxygenation (ECMO) circuits have identified
octanol-water partition coefficient (logP, a marker of lipophilicity) and protein binding (PB) as key drug factors
affecting pharmacokinetics (PK) during ECMO. Using ovine models, in this study we investigated whether these
drug properties can be used to predict PK alterations of antimicrobial drugs during ECMO.
Methods: Single-dose PK sampling was performed in healthy sheep (HS, n = 7), healthy sheep on ECMO (E24H,
n = 7) and sheep with smoke inhalation acute lung injury on ECMO (SE24H, n = 6). The sheep received eight
study antimicrobials (ceftriaxone, gentamicin, meropenem, vancomycin, doripenem, ciprofloxacin, fluconazole,
caspofungin) that exhibit varying degrees of logP and PB. Plasma drug concentrations were determined using
validated chromatographic techniques. PK data obtained from a non-compartmental analysis were used in a linear
regression model to predict PK parameters based on logP and PB.
Results: We found statistically significant differences in pH, haemodynamics, fluid balance and plasma proteins
between the E24H and SE24H groups (p < 0.001). logP had a strong positive linear relationship with steady-state
volume of distribution (Vss) in both the E24H and SE24H groups (p < 0.001) but not in the HS group (p = 0.9) and no
relationship with clearance (CL) in all study groups. Although we observed an increase in CL for highly PB drugs in
ECMO sheep, PB exhibited a weaker negative linear relationship with both CL (HS, p = 0.01; E24H, p < 0.001; SE24H,
p < 0.001) and Vss (HS, p = 0.01; E24H, p = 0.004; SE24H, p =0.05) in the final model.
Conclusions: Lipophilic antimicrobials are likely to have an increased Vss and decreased CL during ECMO. Protein-
bound antimicrobial agents are likely to have reductions both in CL and Vss during ECMO. The strong relationship
between lipophilicity and Vss seen in both the E24H and SE24H groups indicates circuit sequestration of lipophilic
drugs. These findings highlight the importance of drug factors in predicting antimicrobial drug PK during ECMO
and should be a consideration when performing and interpreting population PK studies.* Correspondence: kiran.shekar@health.qld.gov.au
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With refinements in technology, extracorporeal mem-
brane oxygenation (ECMO) and extracorporeal life
support (ECLS) in general now represent a significant
development in intensive care practice [1–4]. A wide
range of acutely ill patients with cardiorespiratory fail-
ure are now being successfully rescued with ECLS
therapies, but clinicians await definitive evidence sup-
porting their use. Invasive ECLS therapies such as
ECMO are complex supportive interventions, and out-
comes rely not only on technology but also on user
experience [5]; optimisation of other aspects of intensive
care unit (ICU) management, established processes and
other available services in each centre; and optimisa-
tion of pharmacotherapy to minimise and/or treat com-
plications [6].
A variety of infectious and non-infectious conditions
may result in severe cardiorespiratory failure, and an in-
fection or sepsis is no longer considered a contraindica-
tion for ECMO [7]. Similarly, patients on ECMO may
develop a variety of ICU-acquired infections that may
necessitate antimicrobial therapy. Optimal antimicrobial
therapy in these patients is a balance between potency,
bacterial susceptibility and exposure [8, 9]. The authors
of a recent review identified 30.1 infections per 1000 days
of ECMO among patients with infections who were ex-
periencing prolonged ICU and hospital lengths of stay
[10]. The authors of another review [11] identified a
total of 2418 infections in 20,741 (12 %) ECMO cases,
with increased morbidity seen in patients with infections.
Antimicrobial therapy is commonly prescribed in ECMO
patients, and optimisation of dosing is central not only to
improving patient outcomes but also to minimising the
emergence of microbial resistance [8].
However, ECMO is known to induce significant phar-
macokinetic (PK) alterations [12] in critically ill patients
who already exhibit significantly altered PK [13], raising
concerns of therapeutic failure or toxicity. Neonatal
studies have shown major variations in antibiotic PK
during ECMO [12, 14–16], and there is an emerging body
of literature to support this in adult patients [17–20]. The
interaction between the drug, the ECMO device and the
disease are complex; hence clinical population PK studies
alone may not be able to advance understanding of mech-
anisms behind altered PK in ECMO patients. This calls
for systematic investigation [21] of each of these factors.
To this end, experimental studies [22, 23] using circuit
components used in adults have shown significant drug
sequestration in ECMO circuits based on physicochemical
properties of the drug, such as drug stability, octanol-
water coefficient (logP, a marker of lipophilicity) and
protein binding (PB).
Ex vivo experimental conditions are quite different
from in vivo scenarios. The addition of an extracorporealcircuit to a critically ill patient may result in profound
PK alterations, and appreciating the relative contribu-
tions of drug, device and disease factors to altered PK is
challenging. Building on the data derived from ex vivo
circuit studies, we aimed to develop PK models for anti-
biotic study drugs that exhibit wide a range of logP and
PB in ambulatory healthy sheep (HS) as well as in
healthy and critically ill sheep on ECMO. We hypothe-
sised that the drug properties logP and PB can be used
to predict PK alterations of antimicrobial drugs during
ECMO.
Methods
Ethical approval was obtained from the Queensland
University of Technology Animal Ethics Committee
(approval number 1100000053) and the University of
Queensland Animal Ethics Committee (approval num-
ber QUT/194/12). All experimentation was done in
accordance with the National Health and Medical Re-
search Council’s Australian Code for the Care and Use of





Seven HS weighing 46–51 kg were housed in a meta-
bolic cart amongst a larger flock, with free access to food
and water. Two three-lumen central venous catheters
were inserted in the left and right internal jugular veins
(IJVs) while the animals were under local anaesthesia for
drug administration and PK sampling. The catheters
were secured with adhesive glue and a sleeve dressing
around the neck. Study drugs were infused for 30 mi-
nutes, and serial blood samples were obtained for drug
assays using validated chromatographic methods and
subsequent PK analysis.
Healthy sheep on ECMO
We performed PK sampling in seven healthy sheep on
extracorporeal membrane oxygenation (E24H). A de-
tailed description of our ovine model of venovenous
ECMO is provided elsewhere [21, 24]. Briefly, a central
venous line was placed in the right IJV while the animals
were under local anaesthesia. Alfaxalone, ketamine and
midazolam were used for induction and maintenance of
anaesthesia. Buprenorphine 0.01 mg/kg was used for
supplemental analgesia. Sheep were intubated and venti-
lated with a Hamilton Galileo ventilator (Hamilton Medical
AG, Bonaduz, Switzerland). The facial artery was cannu-
lated for invasive arterial blood pressure monitoring. A
pulmonary arterial catheter provided continuous measure-
ments of central venous pressure, mixed venous oxygen
saturation and continuous cardiac output (CCO).
Table 1 Lipophilicity and protein binding characteristics of
study drugs









A higher numeric value for octanol-water partition coefficient (logP) indicates
greater lipophilicity [29]
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mals in supine position. A 21-French (50 cm) CAR-
MEDA BioActive Surface–coated (CBAS®; Carmeda,
Upplands Väsby, Sweden) venous cannula (Medtronic,
Minneapolis, MN, USA) was inserted into the right IJV
using a Seldinger technique and positioned using intra-
cardiac echocardiography (ICE) [25] in the proximal
inferior vena cava. A 19-French (50 cm) CARMEDA-
coated femoral venous cannula was used for return
blood and was inserted in the right IJV and positioned at
the superior vena cava right atrium using ICE. ECMO
pump speeds were titrated to target flows at least two-
thirds of pre-ECMO CCO (or 60–80 ml/kg). Immedi-
ately upon commencement of ECMO, study drugs were
infused for 30 minutes and serial blood samples were
obtained for drug assays using validated chromatographic
methods and subsequent PK analysis.
Smoke inhalation acute lung injury sheep on ECMO
We performed PK sampling in six sheep with smoke in-
halation acute lung injury on ECMO (SE24H). The an-
aesthesia and ECMO techniques we used are described
in the previous section. Smoke inhalation acute lung in-
jury (S-ALI) was induced using a validated, reproducible
technique previously published [26]. Briefly, a stainless
steel plate was heated to 750 °C and placed on top of 8 g
of cotton in a cup. The smoke resulting from combus-
tion collected in the bellows of the purpose-built
device was delivered to the sheep by manual com-
pression (tidal volume [VT], 10–12 ml/kg) to achieve
a carboxyhaemoglobin content of 45–50 %. The sheep
were ventilated using Acute Respiratory Distress Syn-
drome Network criteria (VT 4–6 ml/kg, positive end-
expiratory pressure 10–15 cm H2O) for lung-protective
ventilation [27]. Once ECMO was established, study drugs
were infused for 30 minutes and serial blood samples were
obtained for drug assays using validated chromatographic
methods and subsequent PK analysis.
Study drugs, drug administration and pharmacokinetic
sampling
Following baseline sampling, study drugs in identical
doses were administered to the HS, E24H and SE24H
groups. The chosen anti-infective study drugs exhibit a
wide range of logP and PB (Table 1). The intravenous (IV)
study drugs (doses, administration techniques) used were
meropenem (500 mg, bolus), ceftriaxone (500 mg, IV
bolus), gentamicin (240 mg, slow IV bolus), vancomycin
(500 mg in 50 ml 0.9 % saline, IV for 30 minutes), flucona-
zole (100 mg in 50 ml of 0.9 % saline, IV for 30 minutes),
caspofungin (50 mg in 100 ml of 0.9 % saline, IV for 30 mi-
nutes), ciprofloxacin (100 mg in 50 ml of 0.9 % saline, IV
for 30 minutes) and doripenem (500 mg in 100 ml of
0.9 % saline, IV for 30 minutes). Serial blood samples(2 ml) were obtained at 15, 30, 45, 60, 90, 180, 360, 480
and 720 minutes after commencement of antibiotic drug
infusions for drug assays and subsequent PK analysis.Antimicrobial drug assays
Meropenem, doripenem, ceftriaxone and vancomycin
analysis was done using high-performance liquid chro-
matography (HPLC) on a Prominence Ultra Fast system
(Shimadzu, Kyoto, Japan) with ultraviolet light detection
at 304 nm (meropenem and doripenem) and 230 nm
(ceftriaxone and vancomycin). Ciprofloxacin was ana-
lysed on a Prominence HPLC system with fluorescence
detection at 278 nm (excitation) and 456 nm (emission).
Caspofungin, gentamicin and fluconazole analysis was
carried out using liquid chromatography–tandem mass
spectrometry on a Shimadzu Nexera-8030+ system with
detection by positive mode multiple reaction monitoring.
Samples were prepared by protein precipitation with
trichloroacetic acid (ciprofloxacin and gentamicin),
acetonitrile (caspofungin and fluconazole) or acetonitrile
with dichloromethane washing (meropenem, ceftriaxone,
vancomycin and doripenem). Chromatography was
carried out using reversed-phase C18 HPLC columns
(meropenem, ceftriaxone, vancomycin, doripenem, cipro-
floxacin), reversed-phase C8 HPLC columns (caspofungin,
fluconazole) or high-performance liquid chromatography
(HPLC) (gentamicin). All methods were validated accord-
ing to the guidelines of the US Food and Drug Adminis-
tration [28]. All samples were assayed with internal
standards, alongside calibration standards and quality con-
trol samples, and met the acceptance criteria.Statistical analysis and pharmacokinetic modelling
Discrete variables were expressed as count (percentage)
and continuous variables as mean ± SD. Demographics and
clinical differences between study groups were assessed
using a χ2 test, Fisher’s exact test or Student’s t test, as ap-
propriate. p < 0.05 was considered statistically significant.
Table 2 Demographic and physiologic data at baseline
after initiation of anaesthesia, mechanical ventilation and
haemodynamic monitoring and before smoke inhalation and
commencement of ECMO
Group Mean SD p Value
Weight, kg E24H 48.5 4.6 0.84
SE24H 49.6 4.4
Heart rate, beats/min E24H 116 13 0.78
SE24H 118 11
Mean arterial BP, mmHg E24H 116.1 6.8 0.91
SE24H 115.7 8.1
Mean PAP, mmHg E24H 24.6 2.8 0.06
SE24H 21.2 3.2
CVP, cmH2O E24H 15.6 2.8 0.06
SE24H 12.2 3.2
CCO, L/min E24H 5.44 0.93 0.33
SE24H 5.03 0.46
SvO2, % E24H 78.8 7.1 0.31
SE24H 82.0 4.1
PEEP, cmH2O E24H 8.1 2.6 0.67
SE24H 7.5 2.7
Respiratory rate, breaths/min E24H 10.9 6.0 0.6
SE24H 12.5 5.2
Fluid balance, ml E24H 681 376 0.11
SE24H 926 68
Haemoglobin, g/L E24H 7.0 1.2 0.47
SE24H 7.6 1.7
pH E24H 7.385 0.031 0.62
SE24H 7.397 0.052
Body temperature, °C E24H 38.26 0.61 0.67
SE24H 38.13 0.50
Lactate, mmol/L E24H 1.34 0.44 0.17
SE24H 1.07 0.24
Midazolam dose, mg/h E24H 14.4 1.2 0.17
SE24H 15.0 0.0
Urine output, ml/h E24H 69 44 0.87
SE24H 74 68
Albumin, g/L E24H 37.16 2.53 0.33
SE24H 38.15 0.86
Alanine aminotransferase (U/L) E24H 11.7 2.1 0.51
SE24H 12.4 1.7
Serum bilirubin, μmol/L E24H 2.16 0.69 0.75
SE24H 2.03 0.74
Serum creatinine, μmol/L E24H 88 15 0.94
SE24H 87 11
Table 2 Demographic and physiologic data at baseline
after initiation of anaesthesia, mechanical ventilation and
haemodynamic monitoring and before smoke inhalation and
commencement of ECMO (Continued)
Total protein, g/L E24H 71.7 6.4 0.78
SE24H 71.0 1.9
Urine creatinine, μmol/L E24H 10,172 3798 0.17
SE24H 15,541 8009
BP blood pressure, PAP pulmonary arterial pressure, CVP central venous
pressure, CCO continuous cardiac output, SvO2 mixed venous oxygen
saturation, PEEP positive end-expiratory pressure
Data presented are derived from comparison of the results between groups:
healthy sheep on extracorporeal membrane oxygenation (E24H) (n = 7), sheep
with smoke inhalation acute lung injury on extracorporeal membrane
oxygenation (SE24H) (n = 6)
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changes in concentration over time whilst controlling
for repeated results from the same sheep. The result ad-
justs for changes over time and repeated results from
the same sheep. The concentration versus time curves
(mean ± SEM) were plotted using GraphPad Prism ver-
sion 5.03 software (GraphPad Software, La Jolla, CA,
USA). PK analysis of antibiotic concentrations was
undertaken using a non-compartmental approach. All
statistical analyses were done using R version 3.1.2 soft-
ware (R Foundation for Statistical Computing, Vienna,
Austria).
We compared the statistical data between the three
groups using a box plot. To look for a difference in the
mean statistics between groups, we used a linear model
with group as the dependent variable. Because the PK
data were strongly positively skewed, we log-transformed
them before building regression models. Regression
models were derived to examine the differences in the
following PK parameters between the three study groups:
area under the curve (AUC), mean resident time, clear-
ance (CL), steady-state volume of distribution (Vss), max-
imum plasma concentration and minimum plasma
concentration. A linear regression analysis was used to
predict PK parameters based on drug properties. logP data
for the individual drugs are available from the University
of Alberta DrugBank website [29].
Results
We observed no complications during the ECMO run.
We found no significant differences between the physio-
logic variables at the baseline (Table 2). Differences in
physiologic variables between the E24H and SE24H
groups are presented in Table 3. We found statistically
significant differences in pH, haemodynamics, fluid bal-
ance and plasma proteins between the E24H and SE24H
groups (p < 0.001).
Sixteen hundred samples were analysed for study drug
concentrations. Concentration versus time curves for
Table 3 Mean differences in Physiologic parameters of E24H and
SE24H groups during the pharmacokinetic sampling interval
Variable Mean Lower Upper p Value
Heart rate 1.41 −9.54 12.36 0.815
Mean arterial BP −23.83 −31.35 −16.25 <0.001
Mean PAP 1.77 −0.83 4.37 0.234
CVP 0.93 −3.00 4.86 0.669
CCO −2.09 −3.30 −0.87 0.01
SvO2 −0.78 −3.31 1.74 0.585
PEEP 2.09 0.66 3.52 0.02
Respiratory rate (sheep) 2.33 0.18 4.48 0.068
Tidal volume −38.24 −135.38 58.87 0.479
FiO2 7.77 −2.04 17.69 0.151
paO2 48.05 0.43 95.67 0.053
paCO2 3.12 −0.28 6.52 0.115
Running fluid balance 4604.14 2779.38 6428.89 <0.001
ctHb 2.00 1.34 2.66 <0.001
pH −0.07 −0.10 −0.03 0.003
Body temperature −0.06 −0.38 0.27 0.754
Lactate 0.71 0.26 1.16 0.013
Midazolam dose per hour −5.97 −21.37 9.42 0.485
Urine output 6.68 −54.88 68.25 0.843
Albumin −14.91 −16.70 −13.10 <0.001
ALT 5.12 −6.25 16.49 0.419
AST 82.87 −23.66 189.39 0.175
Bilirubin (Direct) −0.48 −1.68 0.73 0.476
Bilirubin (Total) −0.12 −0.71 0.50 0.823
Creatinine 0.56 −11.52 12.64 0.933
Total protein −26.60 <0.001
Urea 0.79 −0.47 2.06 0.271
Urine creatinine −4327.47 −9508.52 974.49 0.322
BP blood pressure, PAP pulmonary arterial pressure, CVP central venous
pressure, CCO continuous cardiac output, SvO2 mixed venous oxygen
saturation, PEEP positive end-expiratory pressure, FiO2 fraction of inspired
oxygen, paO2 partial pressure of oxygen, paCO2 partial pressure of carbon
dioxide, ctHb concentration of total blood haemoglobin, ALT alanine
aminotransferase, AST aspartate aminotransferase
The analysis was carried out using a mixed model with a random intercept for
each sample. The results are presented as mean difference and 95 %
confidence intervals, including a linear time trend and using each sheep’s
baseline (time 0) as a covariate
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PK parameters estimated using a non-compartmental
analysis is presented in Table 4. Significant differences in
AUC between groups were found for ciprofloxacin, gen-
tamicin and caspofungin. For ciprofloxacin, the most
lipophilic drug studied, there was a significant difference
in Vss between the E24H and SE24H groups (p = 0.004).
For relatively protein-bound drugs, there was a trend to-
wards increased Vss only in the SE24H group compared
with HS group. However, an increase in CL was seen inboth the E24H and SE24H groups compared with the
HS group for vancomycin (p = 0.02 for both), ceftriaxone
(p = 0008 and p = 0.05, respectively) and caspofungin
(p < 0.001 for both), which are relatively more
protein-bound.
Scatterplots and linear regression of both CL and Vss
against logP and PB are presented in Figs. 2 and 3.
Table 5 shows regression parameters for predicting study
drug PK using logP and PB. PB exhibited a weaker
negative linear relationship with CL (HS, p = 0.01; E24H,
p < 0.001; SE24H, p < 0.001) and with Vss (HS, p = 0.01;
E24H, p = 0.004; SE24H, p =0.05). Despite an increased
CL for more protein-bound study drugs, PB in itself was
a predictor of decreased CL in all study groups (Table 5).
logP had a strong positive linear relationship with Vss in
both E24H and SE24H (p < 0.001) but not in HS (p = 0.9).
There was no significant association of logP with CL (HS,
p = 0.55; E24H, p = 0.74; SE24H, p = 0.24).
Discussion
In this study, we systematically investigated the effects of
the ECMO circuit on PK in HS and the combined effects
of ECMO circuit and critical illness on PK in S-ALI sheep
receiving ECMO. In addition, by using antimicrobials with
a range of logP and PB, we were also able to investigate
the relative contributions of drug, circuit and disease fac-
tors influencing PK during ECMO.
There was some expected variability in PK parameters
between the groups. Overall, the main findings of the
study are that (1) a significant increase in Vss for lipo-
philic drugs that was observed only in the ECMO sheep
and (2) protein-bound drugs exhibited decreased CL
and CL was also more significantly reduced in ECMO
sheep. These findings are significant, as they conform to
PK alterations described in neonates in the clinical
ECMO setting and to emerging PK data in adults, and
they provide further insights into mechanisms behind
these PK alterations.
Although an increase in Vss during ECMO has been
described clinically [12] for many antimicrobial and
sedative drugs, the relative contribution of critical ill-
ness, circuit and drug factors towards this phenomenon
is largely unclear. Systemic inflammation, capillary leak
syndrome and hypoproteinaemia during critical illness
can result in a significantly increased Vss [13]. Similarly,
sequestration of drugs in ECMO circuits may lead to a
further increase in Vss. Equally, a reduction in drug CL
during critical illness may result from renal and hepatic
dysfunction [13]. This study confirms both these find-
ings. An increase in Vss for lipophilic drugs occurred in
both E24H and SE24H but not in HS, clearly highlight-
ing the role of circuit drug sequestration. For all study
drugs except ciprofloxacin, we found no significant dif-
ference in Vss between the E24H and SE24H groups,
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Fig. 1 Concentration versus time curves for study drugs. a Meropenem. b Vancomycin. c Ceftriaxone. d Ciprofloxacin. e Fluconazole. f
Doripenem. g Caspofungin. h Gentamicin. E24H healthy sheep on extracorporeal membrane oxygenation, HS healthy sheep, SE24H sheep with
smoke inhalation acute lung injury on extracorporeal membrane oxygenation
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Table 4 Non-compartmental pharmacokinetic estimates for eight study drugs for all three study groups
Study drug Group Cmax (mg/L) Cmin (mg/L) AUC0–∞ (mg/h/L) Vss (L) Clearance (L/h) MRT (h)
Ceftriaxone HS 71 (14) 0.0 (0.1) 202 (46) 9.0 (1.8) 2.6 (0.6) 3.5 (0.2)
E24H 86 (15) 1.2 (1.4) 135 (74)a 6.3 (1.4)a 4.3 (1.4)a 1.7 (0.8)a
SE24H 85 (18) 1.0 (0.3)b,c 142 (39) 7.4 (1.8) 3.6 (0.8) 2.1 (0.6)b
Vancomycin HS 48 (9) 0.0 (0) 180 (37) 12.4 (2.6) 2.8 (0.7) 4.5 (0.2)
E24H 52 (10) 1.59 (0.9)a 131 (60)a 15.7 (3.9) 4.0 (1.1)a 4.0 (0.6)
SE24H 51 (12) 2.2 (0.4)b 116 (20)b 19.3 (3.3)b 3.9 (0.6)b 4.9 (0.7)c
Gentamicin HS 20 (2) 0.0 (0) 78 (7) 13.0 (1.3) 3.1 (0.3) 4.3 (0.1)
E24H 12 (6)a 0.3 (0.3)a 25 (12)a 34 (23.5)a 12.1 (7.4)a 2.7 (0.5)a
SE24H 16 (2)b 0.6 (0.2)b,c 39 (6.5)b 20.1 (2.9)b 5.9 (1.0)b,c 3.5 (0.7)b,c
Meropenem HS 26 (16) 0.0 (0.1) 71 (45) 91.0 (138) 20.9 (28) 3.9 (0.8)
E24H 27 (13) 0.5 (0.4) 36 (26) 16.5 (3.0) 13.8 (4.9) 1.4 (0.9)a
SE24H 29 (7) 0.3 (0.1) 39 (9.0) 19.9 (3.7) 13.2 (2.4) 1.6 (0.3)b
Doripenem HS 26 (17) 0 (0) 73 (47) 63.8 (83) 17.6 (22) 3.5 (0.2)
E24H 30 (6) 0 (0) 42 (20) 17.1 (2.8) 13.5 (4.6) 1.5 (0.9)a
SE24H 28 (6) 0 (0) 39 (8) 20.2 (3.0) 13.1 (2.4) 1.6 (0.2)b
Ciprofloxacin HS 3.3 (0.5) 0 (0) 13.6 (1.8) 31.9 (4.4) 7.2 (0.9) 4.5 (0.3)
E24H 5.1 (1.1)a 0.1 (0.1)a 8.3 (1.5)a 39.0 (7.6)a 11.8 (2.5)a 3.5 (1.2)a
SE24H 5.8 (1.2)b 0.1 (0.1)b,c 10.2 (1.5)b,c 52.7 (9.1)b,c 8.2 (1.2)c 6.4 (0.5)b,c
Fluconazole HS 7.7 (0.9) 0 (0) 48.2 (6.2) 13.3 (2.2) 1.2 (0.3) 12.0 (5.8)
E24H 9.1 (1.2)a 2.6 (0.8)d 51.0 (5.0) 16.7 (2.8)a 1.0 (0.3) 17.1 (5.5)
SE24H 9.2 (1.4)b 2.9 (0.5)b 52.3 (3.5) 17.7 (3.4)b 0.8 (0.5)b 33.7 (29)b
Caspofungin HS 5.7 (1.0) 0 (0) 33.8 (7.3) 10.0 (2.5) 0.8 (0.1) 12.9 (2.6)
E24H 4.8 (0.8) 0.7 (0.2)a 22.3 (6.6)a 14.4 (5.0)a 1.9 (0.4)a 7.6 (1.9)a
SE24H 4.3 (1.3)b 0.4 (0.2)b,c 15.5 (3.7)b,c 18.8 (8.4)b 2.8 (0.9)b,c 7.9 (6.4)b
HS healthy sheep (n = 7), E24H healthy sheep on extracorporeal membrane oxygenation (n = 7), SE24H sheep with smoke inhalation acute lung injury on
extracorporeal membrane oxygenation (n = 6), AUC area under the curve, MRT mean resident time, Vss steady-state volume of distribution, Cmax maximum plasma
concentration, Cmin minimum plasma concentration
aStatistically significant results for E24H group compared with HS group
bStatistically significant results for SE24H group compared with HS group
cStatistically significant differences between E24H and SE24H groups
Shekar et al. Critical Care  (2015) 19:437 Page 7 of 11hence the additional influence of critical illness, if at all,
in increasing Vss was less apparent. The reasons behind
a greater Vss seen in the case of ciprofloxacin in the
SE24H group relative to the E24H group is probably a re-
sult of decreased CL in the SE24H group and may indicate
altered hepatic metabolism. It should be noted that there
was no biochemical evidence of any significant hepatic
dysfunction in our model. Clinicians should consider
circuit sequestration and alterations in hepatic function
when prescribing lipophilic antibiotics. In patients with
presumably preserved hepatic function, lipophilic antibi-
otics may have to be prescribed in higher doses. These
findings need further validation in clinical PK studies.
Even though protein-bound drugs have previously
been shown to be sequestered in ECMO circuits under
physiologic conditions [23] with expected increased Vss,
we observed no significant increase in Vss for these
drugs in the present study. However, there was a trendtowards increased Vss for protein-bound drugs in the
SE24H group. This may have resulted from reduced
plasma protein concentrations in the SE24H group. The
difference in blood pH between the SE24H and E24H
groups was significant and may have affected PB [30, 31]
and circuit sequestration. Given that unbound drug con-
centrations were not measured, further interpretation of
these data is not possible. From a general PK perspec-
tive, protein-bound drugs are expected to have a rela-
tively lower Vss, and during critical illness and ECMO
there is a potential for this to increase due to circuit
sequestration and other critical illness–induced PK alter-
ations [13]. The net increase in Vss in a critically ill pa-
tient on ECMO is therefore challenging to predict on
the basis of mechanistic studies alone. Clinical population
PK studies are therefore indicated.
Decreases in CL of antimicrobial and other drugs dur-
ing ECMO have been reported in previous clinical
Fig. 2 Scatterplots and regression of clearance against octanol-water partition coefficient and protein binding by groups. Healthy sheep (HS, n = 7),
healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane
oxygenation (SE24H, n = 6)
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the basis of logP in the present study, which suggests
that the CL for lipophilic drugs may depend largely on
critical illness factors and hepatic drug metabolism. Se-
questration of drugs in the ECMO circuit by itself is un-
likely to play any significant role in reducing CL for
lipophilic drugs. However, it should be noted that alter-
ations in hepatic blood flow [32] and hepatic dysfunction
may occur in patients before initiation of ECMO or dur-
ing ECMO (especially during venoarterial ECMO initi-
ated in patients with severe cardiac failure), which may
then adversely affect hepatic metabolism of lipophilic
drugs and result in decreased CL. The degree of bio-
chemical hepatic derangement in the SE24H group that
received venovenous ECMO for predominant respiratory
failure may not have been sufficient to influence metab-
olism of lipophilic drugs significantly.
Even though protein-bound drugs appeared to have
more significantly reduced CL in ECMO sheep in the
final model, we observed increased CL in both healthy
and critically ill sheep on ECMO for relatively moreprotein-bound drugs (55 % for vancomycin, 95 % for
ceftriaxone and 97 % for caspofungin) compared with
HS. Interestingly, these three drugs also demonstrated a
trend towards an increased Vss during ECMO, especially
in the SE24H group. This is an interesting finding, given
that protein-bound drugs have been shown to have a
greater propensity for sequestration in ECMO circuits in
the ex vivo setting. This relative increase in CL and a
trend towards an increased Vss for more protein-bound
drugs in ECMO sheep may indicate circuit sequestra-
tion. Equally, an increase in plasma unbound fraction of
these drugs due to heparin displacement [33] may also
have contributed to increased CL and Vss for these drugs.
Although this increased CL was apparent in our ovine
ECMO models with relatively preserved renal function,
this may be of less significance in critically ill patients with
significant renal dysfunction or those on continuous renal
replacement therapy (CRRT). For example, no significant
impact of ECMO on vancomycin CL was observed in a re-
cent clinical population PK study by Donadello et al. [18].
The sheep had normal renal function, at least
Fig. 3 Scatterplots and regression of steady-state volume of distribution (Vss) against octanol-water partition coefficient and protein binding by
groups. Healthy sheep (HS, n = 7), healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep with smoke inhalation acute lung
injury on extracorporeal membrane oxygenation (SE24H, n = 6)
Table 5 Linear regression parameters for predicting PK
parameters using drug properties
Group Dependent Independent Mean Lower Upper p Value
HS CL logP −0.54 −2.37 1.29 0.556
E24H CL logP −0.12 −0.86 0.62 0.744
SE24H CL logP −0.41 −1.09 0.28 0.235
HS CL PB −0.13 −0.22 −0.03 0.01
E24H CL PB −0.08 −0.11 −0.04 <0.001
SE24H CL PB −0.07 −0.10 −0.04 <0.001
HS Vss logP −0.48 −8.43 7.46 0.903
E24H Vss logP 2.85 1.73 3.97 <0.001
SE24H Vss logP 3.84 2.18 5.50 <0.001
HS Vss PB −0.50 −0.92 −0.09 0.017
E24H Vss PB −0.10 −0.17 −0.04 0.004
SE24H Vss PB −0.10 −0.21 0.00 0.056
PB protein binding, logP octanol-water partition coefficient (measure of
drug lipophilicity)
Separate results for each group are presented for healthy sheep (HS, n = 7),
healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep
with smoke inhalation acute lung injury on extracorporeal membrane
oxygenation (SE24H, n = 6) and pharmacokinetic (PK) parameters clearance
(CL) and steady-state volume of distribution (Vss)
Shekar et al. Critical Care  (2015) 19:437 Page 9 of 11biochemically, as opposed to 7 of 11 patients who received
CRRT in the above-mentioned study. This is an important
point to note because kidney injury and relatively lower
CL for vancomycin achieved on CRRT may have negated
an increase in CL during ECMO.
Although ex vivo studies confirm relative stability of
vancomycin in ECMO circuits, they do not replicate the
in vivo situation. A recent ex vivo study showed that,
with drugs with similar PB, lipophilicity becomes the de-
terminant of eventual circuit loss. Vancomycin, although
relatively protein-bound (55 %), is hydrophilic. Hence, it
is possible that, in the in vivo setting, there is a greater
propensity for hydrophilic protein-bound drugs to undergo
circuit sequestration. Appropriately powered clinical popu-
lation PK studies in which investigators compare vanco-
mycin PK in ECMO patients with and without preserved
renal function are needed to address this further, and such
studies are currently underway [34].
In summary, sequestration of lipophilic antibiotics
plays an important role in increasing their Vss during
ECMO. CL of lipophilic drugs is largely dependent on
hepatic drug metabolism, which can be significantly
Shekar et al. Critical Care  (2015) 19:437 Page 10 of 11affected in a subgroup of ECMO patients receiving
venoarterial ECMO for cardiac failure. Although more
protein-bound drugs were found to have relatively higher
CL in this study, PB in isolation may not be a reliable pre-
dictor of CL. Patients on ECMO may have significant
renal dysfunction, which is more likely to influence the
net CL than sequestration alone. Overall, ECMO appears
to decrease antimicrobial CL. These findings need further
validation in clinical studies, and such studies are cur-
rently underway [34].
This animal study has limitations. Apart from inherent
PK variability that is expected in a small sample, the distri-
bution, metabolism and excretion processes in sheep may
differ from those of humans. Despite the SE24H group’s
development of severe cardiorespiratory failure following
S-ALI, the degree of hepatic and renal dysfunction may
not have been sufficient to more fully elucidate the full
impact of critical illness of PK. However, the changes in
PK due to critical illness are very well described, and the
use of a model with no advanced end-organ failures that is
designed to more fully examine the circuit–drug interac-
tions is justified. Also, this study was directed more at ob-
serving relative PK changes between groups and the
effects of drug factors logP and PB on antibiotic PK.
Conclusions
Lipophilic antimicrobial agents are likely to have an
increased Vss and decreased CL during ECMO. Protein-
bound antibiotics are likely to have reductions in both
CL and Vss during ECMO. The strong relationship
between logP and Vss during ECMO indicates circuit
sequestration of lipophilic drugs. These findings high-
light the importance of drug factors in predicting
antibiotic drug PK during ECMO and should be a
consideration when performing and interpreting popula-
tion PK studies.
Key messages
 Sequestration of lipophilic antibiotics results in
increased Vss on ECMO.
 Lipophilic drugs exhibit a larger Vss during
ECMO, and lipophilicity by itself has little impact
on drug CL.
 Protein-bound drugs may have decreased Vss and
CL during ECMO.
 Higher doses of lipophilic antibiotics may
be indicated in patients with intact hepatic
function.
 Lipophilicity and PB are useful drug factors
to use in predicting antibiotic PK during ECMO.
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